{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T18:07:42Z","timestamp":1773338862251,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014101","name":"Novavax Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014101","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jinf.2024.106285","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T20:26:00Z","timestamp":1727468760000},"page":"106285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial"],"prefix":"10.1016","volume":"89","author":[{"given":"Chijioke","family":"Bennett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaheer","family":"Hoosain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthonet","family":"Koen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umesh","family":"Lalloo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"Louw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9664-7350","authenticated-orcid":false,"given":"Vongane","family":"Maluleke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1503-2016","authenticated-orcid":false,"given":"Faeezah","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8515-727X","authenticated-orcid":false,"given":"Gabriella","family":"Benade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esme Louise","family":"Venter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirley","family":"Galbiati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shabir A.","family":"Madhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jinf.2024.106285_bib1","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.1016\/S2352-3018(21)00151-X","article-title":"Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study","volume":"8","author":"Jassat","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jinf.2024.106285_bib2","unstructured":"World Health Organization. WHO Global Clinical Platform for Covid-19. Data for public health response. Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection; July 15, 2021. Available at: \u3008https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Clinical-HIV-2021.1\u3009 [Accessed October 15, 2023]."},{"issue":"9","key":"10.1016\/j.jinf.2024.106285_bib3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of antiretroviral therapy in early asymptomatic HIV infection","volume":"373","author":"Insight Start Study Group","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jinf.2024.106285_bib4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/imr.12079","article-title":"HIV-associated chronic immune activation","volume":"254","author":"Paiardini","year":"2013","journal-title":"Immunol Rev"},{"issue":"10","key":"10.1016\/j.jinf.2024.106285_bib5","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/nm1482","article-title":"Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction","volume":"12","author":"Trautmann","year":"2006","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jinf.2024.106285_bib6","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/cid\/cis549","article-title":"Influenza-related mortality among adults aged 25-54 years with AIDS in South Africa and the United States of America","volume":"55","author":"Cohen","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jinf.2024.106285_bib7","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJM198703053161015","article-title":"Accelerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV","volume":"316","author":"Biggar","year":"1987","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jinf.2024.106285_bib8","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1097\/QAD.0b013e32833c6d5c","article-title":"Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals","volume":"24","author":"Tebas","year":"2010","journal-title":"AIDS"},{"issue":"13","key":"10.1016\/j.jinf.2024.106285_bib9","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0264-410X(99)00389-8","article-title":"Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load","volume":"18","author":"Rey","year":"2000","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.jinf.2024.106285_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jinf.2024.106285_bib11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2116185","article-title":"Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico","volume":"386","author":"Dunkle","year":"2022","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.jinf.2024.106285_bib12","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jinf.2024.106285_bib13","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2352-3018(22)00041-8","article-title":"Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A\/2B trial","volume":"9","author":"Madhi","year":"2022","journal-title":"Lancet HIV"},{"issue":"29","key":"10.1016\/j.jinf.2024.106285_bib14","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1016\/j.vaccine.2023.05.051","article-title":"Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373","volume":"41","author":"Alves","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jinf.2024.106285_bib15","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/14760584.2023.2218913","article-title":"Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine","volume":"22","author":"Underwood","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jinf.2024.106285_bib16","unstructured":"United States Food and Drug Administration. Letter of Approval; May 11, 2023. Available at: \u3008https:\/\/www.fda.gov\/media\/159902\/download?attachment\u3009 [Accessed September 27, 2023]."},{"key":"10.1016\/j.jinf.2024.106285_bib17","unstructured":"Novavax. FACT Sheet for healthcare providers administering vaccine (vaccination providers). Emergency use authorization (EUA) Of the Novavax Covid-19 vaccine, adjuvanted to prevent coronavirus disease 2019 (Covid-19). Revised: May 26, 2023. Novavax, Inc., Gaithersburg, MD [Accessed September 27, 2023]. https:\/\/www.novavaxcovidvaccine.com\/."},{"issue":"4","key":"10.1016\/j.jinf.2024.106285_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.9135","article-title":"Safety, immunogenicity, and efficacy of the NVX-CoV2373 COVID-19 vaccine in adolescents: a randomized clinical trial","volume":"6","author":"Anez","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"13","key":"10.1016\/j.jinf.2024.106285_bib19","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.jinf.2024.106285_bib20","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa2103055","article-title":"Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant","volume":"384","author":"Shinde","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jinf.2024.106285_bib21","doi-asserted-by":"crossref","first-page":"e568","DOI":"10.1016\/S2352-3018(21)00157-0","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B\/2A trial","volume":"8","author":"Madhi","year":"2021","journal-title":"Lancet HIV"},{"issue":"6549","key":"10.1016\/j.jinf.2024.106285_bib22","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1126\/science.abh1282","article-title":"Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose","volume":"372","author":"Reynolds","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jinf.2024.106285_bib23","unstructured":"Clinicaltrials.gov. NCT05112848. A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19); 16 March 2023. \u3008https:\/\/clinicaltrials.gov\/study\/NCT05112848\u3009 [Accessed 10 November 2023]."},{"key":"10.1016\/j.jinf.2024.106285_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2024.114945","article-title":"Validation of a severe acute respiratory syndrome coronavirus 2 microneutralization assay for evaluation of vaccine immunogenicity","volume":"327","author":"Hamilton","year":"2024","journal-title":"J Virol Methods"},{"issue":"7","key":"10.1016\/j.jinf.2024.106285_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms11071789","article-title":"A severe acute respiratory syndrome coronavirus 2 anti-spike immunoglobulin G assay: a robust method for evaluation of vaccine immunogenicity using an established correlate of protection","volume":"11","author":"Zhu","year":"2023","journal-title":"Microorganisms"},{"issue":"1","key":"10.1016\/j.jinf.2024.106285_bib26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41467-022-35768-3","article-title":"Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial","volume":"14","author":"Fong","year":"2023","journal-title":"Nat Commun"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324002196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324002196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T23:13:57Z","timestamp":1744154037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445324002196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0163445324002196"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106285","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106285","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106285"}}